On January 27, 2026, the Centers for Medicare & Medicaid Services (CMS) announced lower costs for an additional 15 drugs used to treat cancer and other chronic diseases.
With these cuts, your clients with Medicare Part B and Part D may see lower prescription drug costs in 2028! Keep reading to see the next round of drugs Medicare’s negotiating.
What Are the Newest Maximum Fair Prices (MFPs)?
Effective January 1, 2028, the Maximum Fair Prices (MFPs) for the next 15 Medicare-negotiated drugs brings the total number of negotiated drugs to 40.
2028 Maximum Fair Prices for Medicare-Negotiated Drugs
Source: CMS.gov
Note: Numbers are rounded to nearest thousands. Conditions listed under commonly treated conditions are limited to conditions for which prescription drug coverage or payment is currently available under the Medicare Part B and/or D program and is not intended to be exhaustive.
*The selected drug name reflects the manufacturer’s naming convention, and use of the manufacturer’s assigned name when describing the selected drug is not indicative of any change in Medicare coverage or payment for this selected drug when used for cosmetic purposes.
How Will This Program Evolve?
As long as a drug remains in the Medicare Drug Price Negotiation Program, a discount will apply.
For every year a drug remains in the program; CMS will adjust the price by the annual percentage increase in the Consumer Price Index for all urban consumers. The cost may also include any other updates based on renegotiations between CMS and drug manufacturers.
Do Manufacturers Have to Participate in the Medicare Drug Price Negotiation Program?
No. The participation of drug companies in the program is voluntary.
Participating manufacturers must ensure the negotiated price is available to eligible individuals, pharmacies, mail-order services, and other entities that dispense the selected drug.
The Future of Medicare Drug Price Negotiation
The Inflation Reduction Act of 2022 gave CMS the power to negotiate the prices of select expensive drugs. Since then, prescriptions have become more affordable for Medicare beneficiaries.
Ten drugs were negotiated for 2026, and 15 drugs were already negotiated for 2027. Moving forward, CMS continue negotiating up to an additional 15 Part B or D drugs every year after 2028.
With more savings expected in the years to come, Part D beneficiaries should be in for a much-needed money reprieve!
As the number of negotiated drugs is set to keep increasing, your Medicare clients affected chronic or critical illnesses may keep benefitting! Ensure that your clients are aware of these and any upcoming changes that could affect their prescription drug costs.
Ritter aims to keep you up to date on all the latest events in the health insurance industry! Register for free today for access to essential information, resources, and tools to enhance your business.
Not affiliated with or endorsed by Medicare or any government agency.
Share Post